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From the earliest descriptions of multiple sclerosis (MS), the venocentric characteristic
of plaques was noted. Recently, numerous magnetic resonance imaging (MRI) studies
have proposed this finding as a prospective biomarker for MS, which might aid in differ-
entiating MS from other diseases with similar MRI findings. High-field MRI studies have
shown that penetrating veins can be detected in most MS lesions using T2∗ weighted
or susceptibility-weighted imaging. Future studies must address the feasibility of imaging
such veins in a clinically practical context. The specificity of this biomarker has been stud-
ied only in a limited capacity. Results in microangiopathic lesions are conflicting, whereas
asymptomatic white matter hyperintensities as well as lesions of neuromyelitis optica are
less frequently venocentric compared to MS plaques. Prospective studies have shown that
the presence of venocentric lesions at an early clinical presentation is highly predictive of
future MS diagnosis. This is very promising, but work remains to be done to confirm or
exclude lesions of common MS mimics, such as acute disseminate encephalomyelitis, as
venocentric. A number of technical challenges must be addressed before the introduction
of this technique as a complementary tool in current diagnostic procedures.
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INTRODUCTION
Demonstration of white matter lesions with magnetic resonance
imaging (MRI) is central to multiple sclerosis (MS) diagnosis (1).
However, white matter hyperintensities (WMHs) are not specific
to MS and may reflect a number of physiological processes other
than inflammatory demyelination (2). Requirements for MS diag-
nosis that demyelinating lesions be proved as disseminated in
space and time should not overshadow the necessity for ruling
out mimics of MS (3).
An early and accurate diagnosis with MS will allow quality of
life to be retained through early initiation of disease-appropriate
management (4). To that end, there is a growing interest in iden-
tifying biomarkers that can facilitate discrimination between MS
and non-MS at first clinical presentation.
One such biomarker may be an MRI-detectable penetrating
vein within a WMH. MS lesions have been known to be veno-
centric since the earliest descriptions of the disease (5). It was not
until 2000 that Tan et al. directly demonstrated this physiological
finding in vivo with MRI (6). Interest in this biomarker has grown
in subsequent years. Many studies have explored the utility of MRI
for discriminating between MS plaques and non-MS WMHs on
the basis of central veins.
Are venocentric WMHs specific to MS? Can this information
be used for earlier diagnosis at clinical field strengths? Claims that
this biomarker “could overhaul current diagnostic algorithms” (7)
in MS must be tempered until all data are vetted and the potential
challenges with this technique are explored and overcome.
In this review, we first summarize relevant evidence in order
to consider the specificity of venocentric lesions to MS. A relevant
overview of imaging techniques is provided. Subsequently, our
main objective is addressed: to review MRI studies which have
explored imaging central veins in WHMs. Finally, we identify nec-
essary challenges which must be overcome prior to bringing this
biomarker into the clinic.
ARE VENOCENTRIC LESIONS UNIQUE TO MS?
IDIOPATHIC INFLAMMATORY DEMYELINATING DISEASE
Multiple sclerosis
In 1868, Charcot reported that sclerotic plaques of MS were typi-
cally positioned along small veins, as determined from analyses of
autopsy specimens (5). Dawson later described MS plaques that
spread along prominent periventricular veins (8) (now known as
Dawson’s fingers). Functionally, the vein is involved in the forma-
tion of the plaque as a necessary substrate for inflammation (9).
Acute disseminate encephalomyelitis
Acute disseminate encephalomyelitis (ADEM) is an immune-
mediated demyelinating disease of the brain that has overlapping
clinical and radiological features with MS (10). Indeed, a consid-
erable portion of patients with suspected ADEM are eventually
diagnosed with MS (11). Pathologically, the hallmark of ADEM
is the narrow sleeve of perivenous inflammatory demyelination
(12), differing from confluent demyelination in MS. It follows
that lesions of ADEM, like those of MS, might appear perivenous
on MRI – an uninvestigated issue.
Neuromyelitis optica
Like ADEM, neuromyelitis optica (NMO) is an immune-mediated
demyelinating disease that is distinct from MS, but shares imaging
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and clinical features (13). A recent study has found that 35%
of WMHs in NMO-spectrum disorders have an MRI-detectable
penetrating vein, as opposed to 92% in MS (14).
NEUROLOGICAL DISEASE WITHOUT PRIMARY DEMYELINATION
Thorough reviews are available which classify mimics of MS that
may present with ambiguous clinical and radiological features
(15), despite distinct underlying pathologies (vascular, autoim-
mune,metabolic,degenerative). There is limited literature describ-
ing venous involvement in pathological correlates of WMHs in
these cases.
A limited number of studies have evaluated the presence of an
MRI-detectable central vein in WMHs in the context of small vessel
disease. Where one study reported the total fraction of venocentric
lesions in Susac syndrome to be significantly reduced compared to
MS (16), a separate study reported that WMHs in general microan-
giopathies and MS were equivalent in this regard (17). Given that
Susac syndrome is ultimately a specific microangiopathy, ques-
tions are raised as to the consistencies of methodology of these
studies.
Generally, rheumatic diseases such as systemic lupus erythe-
matous, Sjögren’s syndrome, and Behçet’s syndrome have systemic
presentations (18). When first presentation is neurological,WMHs
are generally detected. For this reason, the neurologist must rule
out these diseases when considering an MS diagnosis. Given
modest overlap in components of disease pathology in neurolog-
ical manifestations of rheumatic diseases and MS (autoimmune
inflammation,vascular damage, foci of demyelination), it is imper-
ative to address the unexplored possibility that WMHs in these
systemic autoimmune diseases are venocentric.
MRI OF VEINS
Owing to the small size of the veins that are found within MS
lesions (on the order of 100s of microns), commonly used MRI
venography techniques such as time-of-flight or phase contrast are
insufficient for their detection.
T2∗ WEIGHTED IMAGING
T2∗ weighted MR imaging forms the basis of detecting penetrating
veins in MS lesions. T2∗ weighted images differ from T2 and T1
weighted in that they demonstrate increased sensitivity to inho-
mogeneous magnetic field (19). For a large range of magnetic
fields within an imaging voxel, resonating spins will lose coherence
rapidly, resulting in decreased signal intensity within that voxel.
Owing to the paramagnetic nature of deoxyhemoglobin (20),
venous blood will perturb the local magnetic field. In vox-
els containing or adjacent to a vein, the spins will “see” a
larger range of magnetic fields and, due to the above-described
effect, cause reduced signal intensity for the voxel. Thus, in T2∗
weighted images, veins appear hypointense relative to surrounding
tissues (21).
SUSCEPTIBILITY-WEIGHTED IMAGING
Susceptibility-weighted imaging (SWI) is a technique that uses the
phase data (typically discarded in clinical practice) to enhance the
endogenous contrast in the T2∗ weighted magnitude image (22).
In brief, the phase of MRI signal is proportional to the magnetic
field and is thus also sensitive to the presence of venous blood.
A phase “mask” can be created which, when multiplied with the
magnitude image, improves the contrast of veins (i.e., makes veins
more hypointense) without dramatically changing other contrast.
For both T2∗ weighted and SWI images, the visibility of a vein
will depend not only on its size, but also on the dimensions of
the imaging voxel. Best contrast is expected for a voxel that has
a slice thickness that is two to four times the in-plane resolu-
tion (23). At 3 T, it has been estimated that parenchymal veins
with diameters on the order of 100–200µm can be detected for a
0.5 mm× 0.5 mm× 1.0 mm voxel (24).
FLAIR/SWI FUSION
The contrast of lesions may not be optimal on T2∗ or SWI images
compared to FLAIR, the clinical standard for lesion detection. Two
research groups have proposed multiplying the SWI phase mask
with a co-registered FLAIR image to facilitate the simultaneous
visualization of parenchymal veins and lesions (25, 26). Alterna-
tively, one must identify lesions on FLAIR, and then toggle to a
T2∗ weighted or SWI image to identify veins. It is uncertain if
the increased post-processing required for FLAIR/SWI fusion will
increase ability to detect penetrating veins in WMLs.
PREVIOUS WORK
A number of previous studies (Table 1) have undertaken the
objective of visualizing veins in MS lesions, and can be generally
considered in three categories: (1) those which seek to reproduce
the observation that MS lesions tend to be venocentric, (2) those
which seek to determine the specificity of this finding to MS, i.e.,
by determining if venocentric lesions are prevalent in other dis-
eases, and (3) those which seek to determine the predictive value
early in the disease course (for example, at the stage of clinically
isolated syndromes) of venocentric lesions for conversion to MS.
These are addressed below, in turn. As a metric, most studies have
reported fractions of lesions with central veins to total lesions;
herein reduced to percentage of lesions with central veins, or %
LCV for clarity.
CAN CENTRAL VEINS BE DETECTED IN MS LESIONS?
The study of Tan et al. in 2000 was the first to use MRI to demon-
strate that MS lesions are venocentric (6). Notably, this study is
the only one thus far to attempt to do so at 1.5 T, and the results
are remarkable. Using SWI acquired post contrast injection (to
increase venous contrast in magnitude image), this study found
% LCV to be 99. The authors emphasize that given the ubiquitous
nature of small venules, only the correspondence of ovoid lesions
specifically along a vein is typical of MS.
Subsequent studies in 2008 (27, 28) reproduced these findings
at 7T using T2∗ weighted images, although the near-perfect corre-
spondence between lesion and central vein was not reproduced. As
in Tan’s study, Tallantyre et al. noted that nearly all lesions found
near the ventricles were perivenous, an unsurprising finding given
the high density of veins in this region. This potentially reduces
the relevance of rating lesions in this area when considering an
alternative diagnosis to MS, as lesions may be venocentric merely
“by chance.”
Another study compared 7–3 T in terms of ability to demon-
strate central veins in MS plaques using T2∗ weighted imaging,
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Table 1 | Venocentricity studies suggest MRI can be made sensitive to venocentric MS lesions. Specificity of this biomarker to MS is not well
studied.
Study Field (T) Subjects Imaging Voxel size Metric Outcome
Tan et al. (6) 1.5 17 CDMS SWI post-gad 0.65 mm×0.49 mm×
2.50 mm
% LCV Periventricular WM: 100%
deep WM: 98%
Ge et al. (27) 7 2 women with RRMS T2* weighted 0.23 mm×0.23 mm×
2 mm
%LCV 59%
Tallantyre et al. (28) 7 8 CDMS T2* weighted 0.67 mm isotropic % LCV periventricular WM: 96%
peripheral WM: 65%
Tallantyre et al. (29) 3, 7 7 CDMS, 7 HC T2* weighted 7T: 0.5 mm isotropic 3T:
0.8 mm isotropic
% LCV 7T: controls: 8%, MS:
87%; 3T: MS only: 45%
Grabner et al. (25) 3, 7 10 patients with CDMS FLAIR-SWI 0.3 mm×0.3 mm×1.2 mm % LCV 25%
Lummel et al. (17) 3 15 MS, 15 microangiopathy SWAN 0.52 mm×0.52 mm×
2.6 mm
% LCV MS: 80%;
microangiopathy: 78%
Tallantyre et al. (30) 7 28 MS, 17 non-MS with white
matter lesions (12 with
vascular risk factors, 5 HC)
T2* weighted 0.5 mm isotropic % LCV MS: 80%, non-MS: 19%
Sinnecker et al. (14) 7 10 NMO-spectrum disorders,
18 MS
T2* weighted 0.5 mm×0.5 mm×
2.0 mm
% LCV NMO-SDs: 35%, MS: 92%
Wuerfel et al. (16) 7 5 Susac Syndrome (SS), 10
RRMS, 15 HC
T2* weighted 0.5 mm×0.5 mm×
2.0 mm
% LCV SS: 54%; MS: 92%, no
lesions in HC
Kau et al. (31) 3 14 suspected MS; by
follow-up, all were diagnosed
(5 MS)
SWI 0.45 mm×0.45 mm×
1.00 mm
CVS+
lesions
All MS: ≥1 CVS+ lesion;
8/9 non-MS, 0
CVS+ lesions
Mistry et al. (7) 7 29 suspected MS; by
follow-up, 22 were diagnosed
(13 MS)
T2* weighted 0.5 mm isotropic % LCV All MS: >40% at baseline;
all non-MS: <40% at
baseline
HC, healthy controls; % LCV, percentage of all lesions with central veins; CVS, central vein sign [the presence of a central vein in a large lesion (31)].
finding that only half as many lesions could be demonstrated as
such using the lower field strength (29). This finding is puzzling
considering the spectacular results from even lower field strength
(1.5 T) noted above. Potentially, the large isotropic voxels used at
3 T in this study were not as sensitive to veins of diameters typical
in MS lesions.
Grabner et al. used a fusion approach, multiplying a phase
mask derived from 7 T imaging with a 3 T FLAIR image (25).
Veins were found in only a quarter of lesions in the cohort of
10 MS patients. This result is in contrast to the otherwise consis-
tent findings at 7 T using T2∗ imaging alone, suggesting FLAIR-
SWI fusion may not yet be sufficiently refined for imaging this
biomarker.
CAN CENTRAL VEINS BE DETECTED IN WMHs IN OTHER DISEASES?
Lummel et al. compared the % LCV between patients with MS and
those with WMHs related to microangiopathy, finding there to be
equally high prevalence of central veins within WMHs of the two
groups (17). In stark contrast (as pointed out earlier), a later study
compared MS patients against those with Susac syndrome, and
found significant differences in % LCV between the two groups
(16). In the latter study, the authors also investigated the presence
of a hypointense lesion rim on T2∗, suggestive of iron deposition,
which is known from histology. Whereas 41% of lesions in MS
patients had a hypointense rim, this was detected in only 4% of
patients with Susac syndrome.
A significant difference in % LCV between MS and NMO-
spectrum disorders was noted in a different study (14). In this
work, rim hypointensity was again reported, this time in roughly
one quarter of MS patients, as opposed to 2% of NMO-spectrum
disorder patients. As a biomarker, rim hypointensity appears to
have low sensitivity but high specificity to MS.
With respect to asymptomatic WMHs, Tallantyre et al. reported
less than a fifth had a central vein (with no subject above % LCV of
40%), whereas 80% of WMHs in MS did (with no subject below
40%) (30). The authors reported similar values of % LCV in all
subtypes of MS. In this study, the non-MS group consisted of
patients with known vascular risk factors as well as healthy con-
trols. This group was substantially older than MS group [mean age
(range), for non-MS: 60.8 (34–77); for MS: 46.5 (24–65)], mak-
ing it impossible to separate out the effect of age as a risk factor
for WMHs.
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Given the above, the presence of a central vein has emerged as
a highly sensitive marker of MS, with at least modest specificity
in some cases. However, venocentricity of WMHs in numerous
other diseases that often are considered against MS have yet to be
studied in a similar way. This biomarker’s universal specificity to
MS remains to be established.
IS VENOCENTRICITY PREDICTIVE OF AN MS DIAGNOSIS?
Only two prospective studies to date have examined the predictive
power of venocentric lesions for subsequent conversion to MS. In
a 3 T SWI study, Kau et al. found that all study participants (but
one) who, at baseline, had at least one lesion with a central vein
later were diagnosed with MS, whereas all those with suspected MS
at baseline without any venocentric lesions were later diagnosed
with another disorder (31). However, the narrow inclusion crite-
ria [at least 1 large (5 mm) lesion in a patient with suspected MS]
obscure translation of this methodology to the clinic. Mistry et al.
followed 29 patients with suspected MS (7). Diagnosis of MS by
the follow-up at average of 26 months overlapped perfectly with
% LCV >40% at baseline, as examined with 7 T T2∗ imaging. In
both studies, the scope of non-MS diagnoses (i.e., at follow-up)
was limited (mostly vascular disorders).
MOVING FORWARD
Recent evidence, especially from limited but exciting prospective
studies, shows promise for the evaluation of venocentric lesions
in aiding MS diagnosis. However, a number of challenges remain,
described here.
CLINICAL IMPLEMENTATION
It has been established that 3 and 7 T MRI can demonstrate the
presence of a central vein in many MS lesions. No study since
the preliminary work of Tan et al. (6) (which lacked any con-
trol group or blinding) has investigated this promising biomarker
at 1.5 T. While that study benefited from increased SWI contrast
due to use of gadolinium, a trend in MS diagnostic criteria is to
move away from dependence on such agents (1). It thus remains to
be established whether central veins can be demonstrated in MS
lesions at 1.5 T using conventional T2∗ imaging, or more likely,
non-contrast SWI. Multi-echo modifications to SWI remain a pos-
sibility given their increased venous contrast (32), however such
techniques come at the cost of increased scan time. Alternatively,
given the increasing prevalence of 3 T MRI scanners in clinical use,
optimization of a 3 T technique may be sufficient for centers where
such a system is available.
IMAGING PARAMETERS
Venous visibility is intimately linked to voxel dimensions. Sev-
eral studies reviewed here seemingly neglected the finding that
isotropic voxels are not ideal for imaging small veins using SWI
or T2∗ weighted contrasts (23) (see Table 1, “Voxel Size” column).
As a note, a recent paper dealt specifically with the topic of T2∗
MRI at 3 and 7 T for small veins in MS plaques (33). Following
numerical optimization and validation in vivo, the authors pro-
posed revisions to echo times and voxel dimensions implemented
in their previous studies to increase visibility of small veins within
MS lesions (29, 30). Proposed voxel dimensions were incidentally
in line with above-referenced previous optimizations.
VENOCENTRICITY METRIC
The vast majority of studies reviewed here report some version of
what we refer to as % LCV. Given the demonstration of a clean
threshold in this metric to distinguish between MS and non-MS
at baseline (7), this is an enticing approach. There are at least two
challenges to face here.
The first challenge is: what to do in the case of patients
with very small or large lesion burdens? In the first case, what
is the minimum number of lesions that must be rated (and
therefore be present) to obtain a confident evaluation? In the
second case, might it be appropriate to rate only a subset of
the lesions in order to obtain a representative but accurate %
LCV? Using hypergeometric distribution methodology, Tallantyre
et al. reported that if only 10 lesions per patient were rated (in
patients with >10 lesions), the diagnosis of MS/non-MS could
correctly be predicted with 90% certainty in 44 out of 45 patients
tested (30).
The second challenge is: what constitutes a penetrating vein
from a radiological standpoint? The shape of the lesion, and pos-
sibly the course of the vein within are likely relevant. In several
studies, criteria for venocentricity are clearly and unambiguously
outlined; in others, they are absent. It would be best to adopt a
common set of criteria, such as those outlined in the works of the
Nottingham group (28).
SPECIFICITY OF VENOCENTRIC LESIONS TO MS
As speculated above, it is possible that WMHs in non-MS dis-
eases may contain MRI-detectable central veins. In this case, it
may not be possible to discriminate against MS using the central
vein biomarker reviewed here.
Ultimately, the number of diseases that are often differential
diagnoses for MS is too large to allow systematic, disease-by-
disease evaluation of typical % LCV, however common alternatives
to MS should be vetted thoroughly. Given the known perivenous
demyelination in ADEM (12), it is imperative that this disease be
evaluated.
COMPARISONWITH OTHER DISEASE MARKERS
Para-clinical testing such as analyses of CSF, serum, visually evoked
potentials, as well as demographic factors and specific symp-
toms also guide the diagnostic process in MS (1). It is yet to be
determined if the venocentricity biomarker can offer additional
diagnostic accuracy. Only then will its addition to the clinical
toolbox be warranted.
CONCLUSION
In the past decade, numerous studies have explored a
promising biomarker for MS: MRI-detectable veins within lesions.
This biomarker is well established as detectable at 3 and 7 T and
efforts should be made to identify/optimize clinically practical
methods for its evaluation. Prospective studies have shown that
the presence of venocentric lesions at an early but ambiguous
clinical presentation is highly predictive of future MS diagnosis.
Work remains to be done to confirm or exclude lesions of com-
mon MS mimics as venocentric. Common imaging practice and
lesion-rating paradigms should be adopted by scientists working
in this field.
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